In the article titled “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy” [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.
Corrigendum | Open Access
Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”
Received10 Jul 2019
Accepted15 Jul 2019
Published27 Aug 2019
References
E. Choy, K. Ballman, J. Chen et al., “SARC018_SPORE02: phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy,” Sarcoma, vol. 2018, Article ID 2068517, 9 pages, 2018.
View at: Publisher Site | Google Scholar
Copyright
Copyright © 2019 Edwin Choy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.